Monogram gets patent for eTag technology

By Elaine Rigoli

Tampa, Fla., July 25 - Monogram Biosciences, Inc. has received a Notice of Allowance from the U.S. Patent Office for its proprietary eTag technology for detecting protein dimers.

The company said protein dimerization is pivotal in mediating signal transduction and in regulating abnormal cell proliferation that occurs in cancer cells.

Detecting aberrant dimerization and corresponding signal transduction may predict patient prognosis and response to therapy, the company said in a news release.

The patent covers homodimers and heterodimers and is not limited to particular dimer types. Examples of covered dimers are ErbB proteins, such as EFGR and HER2, vascular endothelial growth factor receptors, such as Vegfr2, and G-protein coupled receptors, the release said.

Monogram said the eTag assays may also enable detailed analysis of protein drug targets and signaling pathways in cancer cells using tissue lysates or FFPE specimens, the standard in most pathology labs.

Monogram is a pharmaceutical company based in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.